“Generating superior returns by investing in and building sustainable healthcare businesses”
Impilo at a glance
Impilo is a Nordic investment company with a sole focus on investments in companies operating in the pharmaceutical, medtech, specialist pharma services or other healthcare & related services industries. Our starting point is that our portfolio companies must contribute to positive and sustainable development of the societies and markets in which they operate in order to remain successful in the long term.
This is a conviction that is deeply embedded in our investment strategy and inspires our approach to investments and how we interact with our portfolio companies. In this way, Impilo invests in people’s opportunities to enjoy healthier lives into the future.
Impilo in numbers
Operational since
EURbn raised
Employees
Portfolio companies
Offices
Impilo Annual Report 2025
In our Annual Report 2025, you can read more about the year that has passed, our portfolio companies and how we continue to build sustainable healthcare companies.
Investment focus and criteria
- Impilo targets investments in companies that contribute with positive health impact and/or to the sustainability of healthcare systems
- Target companies active within the full spectrum of healthcare verticals
- Focus on private majority investments, with enterprise values of EUR 50m-200m, but minority and public investments can be considered, subject to relevant governance rights
- Targets must have the potential to double operating profit over 5 years and outgrow relevant markets
The Impilo Health Diamond
The Impilo Health Diamond represents the four key health impact dimensions that we take into consideration in all investments. Any new investment must align with or have the potential to align with one or more of the dimensions to be deemed attractive.
Improve quality of care
We look for companies with products or services that:
- Provide positive treatment outcomes for patients and/or individuals
- Enable companies in the healthcare system to provide higher quality of care, e.g. better patient outcomes and improved quality of treatments
- Are tailored to the specific needs of individual patients and customers
- Improve processes and quality standards in the broader healthcare value chain, e.g. by ensuring products are safe to use compared to alternative treatments
Increase availability of care
We look for companies with products or services that:
- Make healthcare services more easily available or accessible to the people who need them at the time they need them (e.g. by increasing opening hours or opening of new facilities in unserved areas)
- Bring novel treatments to people who did not have access to these treatments before
- Provide scalable solutions (e.g. digital health), which reduce the dependency on in-clinic care
- Help increase capacity within the healthcare sector (e.g. new facilities, increase in healthcare workers etc.)
Lower cost of care
We look for companies with products or services that introduce critical efficiencies and cost-saving benefits compared to alternatives – either directly for patients/individuals and/or for healthcare companies or organisations that purchase them.
Prevent need for care
- Help people not get sick in the first place, e.g., through improved lifestyle choices (exercise, nutrition, etc.) – Primary prevention
- Help detect current or potential diseases early on and prevent them from getting worse – Secondary prevention
Improve quality of care
We look for companies with products or services that:
- Provide positive treatment outcomes for patients and/or individuals
- Enable companies in the healthcare system to provide higher quality of care, e.g. better patient outcomes and improved quality of treatments
- Are tailored to the specific needs of individual patients and customers
- Improve processes and quality standards in the broader healthcare value chain, e.g. by ensuring products are safe to use compared to alternative treatments
Increase availability of care
We look for companies with products or services that:
- Make healthcare services more easily available or accessible to the people who need them at the time they need them (e.g. by increasing opening hours or opening of new facilities in unserved areas)
- Bring novel treatments to people who did not have access to these treatments before
- Provide scalable solutions (e.g. digital health), which reduce the dependency on in-clinic care
- Help increase capacity within the healthcare sector (e.g. new facilities, increase in healthcare workers etc.)
Lower cost of care
We look for companies with products or services that introduce critical efficiencies and cost-saving benefits compared to alternatives – either directly for patients/individuals and/or for healthcare companies or organisations that purchase them.
Prevent need for care
- Help people not get sick in the first place, e.g., through improved lifestyle choices (exercise, nutrition, etc.) – Primary prevention
- Help detect current or potential diseases early on and prevent them from getting worse – Secondary prevention
Impilo sustainability handbook
At Impilo, we are on a mission to invest in and build leading healthcare companies. We consider sustainability a central component of this commitment and believe that the leading healthcare companies of tomorrow are also the most sustainable healthcare companies.
Responsible Investment and Ownership Policy
The Responsible Investment and Ownership Policy describes Impilo’s commitment to sustainability and how we seek to implement our sustainability commitments throughout the investment process and ownership cycle
We are inspired by internationally acknowledged sustainability principles when developing our internal frameworks
News
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.
U.S. FDA has granted accelerated approval of Loargys®
Immedica today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Loargys® (pegzilarginase-nbln), an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction.
Impilo acquires Oticon Medical from Demant
Impilo has agreed to acquire Oticon Medical AB, a global leader in bone-anchored hearing solutions (BAHS), from Demant A/S. The transaction is the first investment from Impilo’s new flagship fund and will support Oticon Medical’s transition to a standalone company while driving growth, advancing next-generation technologies, and improving outcomes for people with hearing loss.